FindTrial
Sign In

Doxycycline Monohydrate

DRUG10 trials

Sponsors

Thomas Gardner, Par Pharmaceutical, Inc., Teva Pharmaceuticals USA, Rochester General Hospital

Conditions

Cutaneous T-cell LymphomaDiabetic RetinopathyHealthyMycosis FungoidesSezary SyndromeTo Determine Bioequivalence Under Fasting ConditionsTo Determine Bioequivalence Under Fed Conditions

Phase 1

Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting Conditions
CompletedNCT00653380
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fasting Conditions
Start: 1999-09-30End: 1999-10-31Updated: 2008-04-04
Bioequivalence Study Doxycycline Tablets and Monodox Capsules Under Fasting Conditions
CompletedNCT00652795
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fasting Conditions
Start: 2004-07-31End: 2004-09-30Updated: 2008-04-04
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
CompletedNCT00652704
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fed Conditions
Start: 1999-07-31End: 1999-09-30Updated: 2017-09-26
Bioavailability Study of Doxycycline Monohydrate Capsules and Monodox Under Fasting and Fed Conditions
CompletedNCT00652704
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fed Conditions
Start: 1999-07-31End: 1999-09-30Updated: 2017-09-26
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fed Conditions
CompletedNCT00829790
Teva Pharmaceuticals USAHealthy
Start: 2006-10-31End: 2006-10-31Updated: 2024-08-19
Doxycycline Monohydrate 25 mg (5mL) Oral Suspension Under Fasting Conditions
CompletedNCT00829764
Teva Pharmaceuticals USAHealthy
Start: 2006-10-31End: 2006-10-31Updated: 2024-08-19
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fed Conditions
CompletedNCT01380496
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fed Conditions
Start: 1999-11-30End: 1999-11-30Updated: 2017-09-26
Bioequivalence Study of Doxycycline Monohydrate Tablets Under Fasting Conditions
CompletedNCT01380483
Par Pharmaceutical, Inc.To Determine Bioequivalence Under Fasting Conditions
Start: 2000-01-31End: 2000-04-30Updated: 2011-06-27

Phase 2

Evaluation of Doxycycline Verses Placebo for the Treatment of Severe Nonproliferative or Mild or Moderate Proliferative Diabetic Retinopathy
CompletedNCT00511875
Thomas GardnerDiabetic Retinopathy
Start: 2008-07-31End: 2012-05-31Updated: 2018-11-02
Evaluation of Effect of Doxycycline Verses Placebo on Retinal Function and Diabetic Retinopathy
CompletedNCT00917553
Thomas GardnerDiabetic Retinopathy
Start: 2009-07-31End: 2012-07-31Updated: 2018-11-30
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma
TerminatedNCT02341209
Rochester General HospitalCutaneous T-cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
Start: 2018-02-06End: 2021-02-06Updated: 2021-04-27

Related Papers

Effect of Doxycycline vs Placebo on Retinal Function and Diabetic Retinopathy Progression in Mild to Moderate Nonproliferative Diabetic Retinopathy
JAMA Ophthalmology2014-06-2628 citations
Effect of Doxycycline vs Placebo on Retinal Function and Diabetic Retinopathy Progression in Patients With Severe Nonproliferative or Non–High-Risk Proliferative Diabetic Retinopathy
JAMA Ophthalmology2014-03-0657 citations